Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis

Bibliographic Details
Main Authors:	N Fleeman, A Bagust, A Boland, R Dickson, Y Dundar, M Moonan, J Oyee, M Blundell, H Davis, A Armstrong, N Thorp
Format:	Article
Language:	English
Published:	NIHR Journals Library 2011-12-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta15420

Similar Items

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01)

Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines
by: 大島, 由記子, et al.
Published: (2014)

Lapatinib for HER2 overexpressing breast cancer
by: Jones, Jeremy, et al.
Published: (2009)

Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Lapatinib for the treatment of HER2-overexpressing breast cancer
by: J Jones, et al.
Published: (2009-10-01)

Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report
by: Xiao-Dong Jiao, et al.
Published: (2018-02-01)

Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
by: Armstrong, A., et al.
Published: (2022)

Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease
by: Lauren Ogawa, et al.
Published: (2018-12-01)

The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis
by: Chen ZL, et al.
Published: (2016-05-01)

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
by: Tejal A. Patel, et al.
Published: (2019-09-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption
by: Christel Larbouret, et al.
Published: (2012-02-01)

Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.
by: Ariel Hammerman, et al.
Published: (2015-01-01)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
by: Yi Li, et al.
Published: (2020-03-01)

Lapatinib, trastuzumab or the combination added to neoadjuvant chemotherapy for breast cancer
by: Quan Liang, et al.
Published: (2016-10-01)

Response and resistance to lapatinib in HER2-overexpressing breast cancer
by: Leung, Wing Yin
Published: (2014)

Lapatinib and capecitabine efficacy at systemic and encephalic level in a patient progressed after dual block of HER2 by trastuzumab and pertuzumab and after T-DM1
by: Andrea Fontana
Published: (2018-06-01)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.
by: Sharad Verma, et al.
Published: (2018-01-01)

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
by: Sara A. Hurvitz, et al.
Published: (2020-11-01)

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
by: Eriko Tokunaga, et al.
Published: (2021-08-01)

Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis
by: Muhammad Khan, et al.
Published: (2020-11-01)

Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy
by: Eugene R. Ahn, et al.
Published: (2012-11-01)

Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues regarding Dual HER2-Targeted Therapy
by: Eugene R. Ahn, et al.
Published: (2012-01-01)

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.
by: Stefania Gori, et al.
Published: (2016-01-01)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
by: Antonio Fernando Leis-Filho, et al.
Published: (2021-06-01)

Role of yes-associated protein in resistance of HER2+ breast cancer to lapatinib
by: CHEN Peng, et al.
Published: (2020-04-01)

Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
by: Hurvitz SA, et al.
Published: (2012-04-01)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
by: Trevor Dennie
Published: (2015-01-01)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
by: Min Ye, et al.
Published: (2021-07-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01)

Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
by: Sae-Won Han, et al.
Published: (2012-01-01)

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
by: Shao Zhimin, et al.
Published: (2011-06-01)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
by: Gabriel L. Fiszman, et al.
Published: (2011-01-01)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
by: Bella Kaufman, et al.
Published: (2008-03-01)

HER2-positive breast cancer with brain metastasis, long responder to lapatinib therapy
by: Chiara Saggia
Published: (2018-06-01)

Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib
by: Elia Romero Carreño, et al.
Published: (2016-03-01)

Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use
by: C. García-Muñoz, et al.
Published: (2014-03-01)